Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-6,969
Closed -$976K 925
2025
Q3
$976K Sell
6,969
-5,922
-46% -$800K 0.15% 219
2025
Q2
$1.62M Buy
12,891
+3,777
+41% +$471K 0.27% 64
2025
Q1
$1.25M Buy
+9,114
New +$1.3M 0.19% 134
2024
Q4
Sell
-7,922
Closed -$1.54M 876
2024
Q3
$1.54M Buy
+7,922
New +$1.66M 0.34% 26
2024
Q2
Sell
-1,974
Closed -$426K 781
2024
Q1
$426K Buy
+1,974
New +$462K 0.09% 430
2023
Q3
Sell
-2,380
Closed -$678K 714
2023
Q2
$678K Buy
+2,380
New +$708K 0.19% 192
2023
Q1
Sell
-1,854
Closed -$513K 668
2022
Q4
$513K Buy
+1,854
New +$524K 0.21% 166
2022
Q3
Sell
-2,862
Closed -$584K 606
2022
Q2
$584K Buy
2,862
+1,255
+78% +$257K 0.29% 87
2022
Q1
$338K Buy
+1,607
New +$349K 0.19% 225
2021
Q4
Sell
-707
Closed -$200K 482
2021
Q3
$200K Buy
+707
New +$232K 0.13% 391
2019
Q4
Sell
-2,394
Closed -$557K 388
2019
Q3
$557K Buy
2,394
+203
+9% +$47.3K 0.51% 28
2019
Q2
$512K Sell
2,191
-79
-3% -$18.2K 0.34% 71
2019
Q1
$537K Buy
2,270
+1,005
+79% +$316K 0.3% 89
2018
Q4
$381K Buy
+1,265
New +$404K 0.2% 195

Other funds holding BIIB

Fox Run Management's BIIB Position: Q4 2025 in Review

Fox Run Management sold out of Biogen (BIIB) in Q4 2025, closing a stake of 6,969 shares — an estimated $976K sold.

Fox Run Management first reported a position in BIIB in Q4 2018 and held it in 14 quarters. The position peaked at $1.62M in Q2 2025. 1,001 funds tracked by Wall St. Rank hold BIIB as of Q4 2025.

  • Fox Run Management reported no remaining Biogen position as of Q4 2025 after selling out during the quarter.
  • Fox Run Management sold 6,969 Biogen shares in Q4 2025, an estimated $976K.
  • Fox Run Management first reported a position in Biogen in Q4 2018 and held it in 14 quarters.
  • Fox Run Management's Biogen position peaked at $1.62M in Q2 2025.
  • 1,001 funds tracked by Wall St. Rank held Biogen as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.